Akoya Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Akoya Biosciences, Inc.

Akoya Biosciences, Inc. (NASDAQ: AKYA) is a United States-based life sciences company listed on the NASDAQ market. It is focused on spatial biology, a segment of the tools and diagnostics industry that helps researchers analyze tissue while preserving cellular context. This is especially relevant in oncology, immunology, neuroscience, and biomarker discovery, where the location of proteins and cells within tissue can be as important as the biology itself. The company is headquartered in Marlborough, Massachusetts, in the Boston life-science corridor, and it grew out of the Phenoptics/spatial imaging platform business before becoming an independent company in the mid-2010s. Akoya’s business model centers on instruments, reagents, multiplex panels, software-enabled workflows, and biopharma services. Its core platforms include PhenoImager and PhenoCycler-Fusion, alongside assay and panel families such as PhenoCode. These products are designed for high-plex tissue imaging and single-cell spatial proteomics, enabling academic labs, translational research centers, contract research organizations, and pharmaceutical companies to generate more actionable tissue-level data. In competitive terms, Akoya occupies a niche but strategically attractive position in the rapidly developing spatial omics market. Its differentiation lies in its specialized technology stack, its focus on high-plex workflows, and its expanding set of applications across drug discovery, biomarker validation, and companion diagnostic development. Geographically, the company serves customers across North America, Europe, and Asia-Pacific, reflecting the global adoption of spatial biology tools in both research and biopharma pipelines. Akoya’s stated mission is to bring context to biology and human health through spatial phenotyping, which captures the company’s role as an enabling platform rather than a traditional therapeutics business. For investors, the model is notable because it combines capital equipment, recurring reagent sales, and service revenue opportunities, which can support longer-term commercial relationships if adoption continues to broaden. Recent developments have been important. In 2025, Akoya expanded its biopharma portfolio with a new assay aimed at antibody-drug conjugate development in breast cancer, and it announced, together with Enable Medicine, the launch of the largest commercially available single-cell spatial proteomics atlas. Another major strategic event in 2025 was the announced merger agreement with Quanterix, highlighting that Akoya is in a period of corporate transition and strategic repositioning. Overall, Akoya Biosciences is a U.S. NASDAQ-listed precision medicine tools company whose outlook is tied to the growth of spatial biology, broader adoption of multiplex tissue analysis, and successful execution of its commercial and strategic roadmap.